Table 1.
Demographics of patients undergoing mastectomy for stage II/III cancer by receipt of immediate breast reconstruction
| Overall (n=5,318) | Mastectomy alone (n=4,626) | Immediate breast reconstruction (n=692) | P value | |
|---|---|---|---|---|
| Demographics | ||||
|
| ||||
| Age | <0.001 | |||
| ≤ 50 | 29.0% (1542) | 24.9% (1152) | 56.4% (390) | |
| > 50 to ≤ 70 | 43.8% (2330) | 44.3% (2048) | 40.7% (282) | |
| > 70 | 27.2% (1446) | 30.8% (1426) | 2.9% (20) | |
| Race | 0.26 | |||
| White | 85.2% (4532) | 84.9% (3928) | 87.3% (604) | |
| Black | 10.8% (576) | 11.1% (512) | 9.2% (64) | |
| Other | 4.0% (210) | 4.0% (186) | 3.5% (24) | |
| Insurance | <0.001 | |||
| Private/managed care | 48.8% (2598) | 44.1% (2042) | 80.3% (556) | |
| Not insured | 2.8% (147) | 2.9% (134) | 1.9% (13) | |
| Medicaid | 8.2% (435) | 8.4% (390) | 6.5% (45) | |
| Medicare or other government | 38.6% (2052) | 42.8% (1979) | 10.6% (73) | |
| Unknown | 1.6% (86) | 1.8% (81) | 0.7% (5) | |
| Charlson-Deyo Comorbidity Index | <0.001 | |||
| 0 | 81.7% (4346) | 80.7% (3732) | 88.7% (614) | |
| 1+ | 14.8% (789) | 15.5% (720) | 10.0% (69) | |
| Unknown | 3.5% (183) | 3.8% (174) | 1.3% (9) | |
|
| ||||
| Tumor characteristics | ||||
|
| ||||
| Stage | 0.001 | |||
| 2 | 64.0% (3405) | 63.2% (2922) | 69.8% (483) | |
| 3 | 36.0%(1913) | 36.8% (1704) | 30.2% (209) | |
| Tumor size | 0.001 | |||
| <2cm | 22.5% (1194) | 22.0% (1017) | 25.6% (177) | |
| 2-5cm | 60.2% (3202) | 60.0% (2770) | 62.4% (432) | |
| >5cm or diffuse/infiltrating | 16.1% (857) | 16.8% (781) | 11.0% (76) | |
| Unknown | 1.2% (65) | 1.2% (58) | 1.0% (7) | |
| Positive nodes | 0.018 | |||
| 0 | 29.9% (1591) | 30.1% (1393) | 28.6% (198) | |
| 1-3 | 39.8% (2118) | 39.2% (1811) | 44.4% (307) | |
| ≥4 | 28.6% (1522) | 28.9% (1340) | 26.3% (182) | |
| Unknown | 1.7% (87) | 1.8% (82) | 0.7% (5) | |
| Tumor Grade | 0.62 | |||
| 1 | 11.4% (606) | 11.5% (532) | 10.7% (74) | |
| 2 | 41.0% (2179) | 40.7% (1881) | 43.1% (298) | |
| 3 | 42.0% (2234) | 42.1% (1949) | 41.2% (285) | |
| Unknown | 5.6% (299) | 5.7% (264) | 5.1% (35) | |
| Receptor subtypes | 0.006 | |||
| ER+ or PR+, /Her2neu− | 58.2% (3095) | 58.0% (2,683) | 59.5% (412) | |
| ER− and PR− /Her2neu− | 14.1% (747) | 14.4% (668) | 11.4% (79) | |
| ER+ or PR+ /Her2neu+ | 12.4% (658) | 12.0% (551) | 15.5% (107) | |
| ER− and PR− /Her2neu+ | 7.1% (380) | 7.1% (329) | 7.4% (51) | |
| ER/PR and/or Her2neu | 8.2% (438) | 8.5% (395) | 6.2% (43) | |
| Unknown | ||||
|
| ||||
| Treatment received | ||||
|
| ||||
| Adjuvant chemo | <0.001 | |||
| None | 30.9% (1645) | 33.4% (1545) | 14.4% (100) | |
| Received | 66.5% (3536) | 64.2% (2972) | 81.5% (564) | |
| Unknown | 2.6% (137) | 2.4% (109) | 4.1% (28) | |
| Endocrine therapy | 0.073 | |||
| None | 41.6% (2211) | 42.0% (1954) | 38.4% (266) | |
| Received | 58.4% (3107) | 58.0% (2681) | 61.6% (426) | |
| Radiation therapy | 0.82 | |||
| None | 62.0% (3296) | 61.9% (2865) | 62.3% (431) | |
| Received | 35.8% (1907) | 36.0% (1663) | 35.2% (244) | |
| Unknown | 2.2% (115) | 2.1% (98) | 2.5% (17) | |
ER, estrogen receptor; PR, progesterone receptor; Her2neu, human epidermal growth factor receptor 2